BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 24506246)

  • 1. CD133-positive stem cells.
    Bian EB; Li J; Zhao B
    J Neurosurg; 2014 Apr; 120(4):1011-2. PubMed ID: 24506246
    [No Abstract]   [Full Text] [Related]  

  • 2. CD133-positive stem cells. Response.
    Tamura K; Aoyagi M
    J Neurosurg; 2014 Apr; 120(4):1012. PubMed ID: 24809085
    [No Abstract]   [Full Text] [Related]  

  • 3. Stem cells and the origin of different glioma subtypes.
    Roesler R
    J Neurosurg; 2014 Apr; 120(4):1009-10. PubMed ID: 24506242
    [No Abstract]   [Full Text] [Related]  

  • 4. Stem cells and the origin of different glioma subtypes. Response.
    Tamura K; Aoyagi M
    J Neurosurg; 2014 Apr; 120(4):1010-1. PubMed ID: 24809083
    [No Abstract]   [Full Text] [Related]  

  • 5. Expansion of CD133-positive glioma cells in recurrent de novo glioblastomas after radiotherapy and chemotherapy.
    Tamura K; Aoyagi M; Ando N; Ogishima T; Wakimoto H; Yamamoto M; Ohno K
    J Neurosurg; 2013 Nov; 119(5):1145-55. PubMed ID: 23991844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of multidrug resistance genes in normal and cancer stem cells.
    Shervington A; Lu C
    Cancer Invest; 2008 Jun; 26(5):535-42. PubMed ID: 18568776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-glioma response of autologous T cells stimulated by autologous dendritic cells electrofused with CD133+ or CD133- glioma cells.
    Qin K; Tian G; Li P; Chen Q; Zhang R; Ke YQ; Xiao ZC; Jiang XD
    J Neuroimmunol; 2012 Jan; 242(1-2):9-15. PubMed ID: 22123613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD133 is essential for glioblastoma stem cell maintenance.
    Brescia P; Ortensi B; Fornasari L; Levi D; Broggi G; Pelicci G
    Stem Cells; 2013 May; 31(5):857-69. PubMed ID: 23307586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recognition and killing of brain tumor stem-like initiating cells by CD8+ cytolytic T cells.
    Brown CE; Starr R; Martinez C; Aguilar B; D'Apuzzo M; Todorov I; Shih CC; Badie B; Hudecek M; Riddell SR; Jensen MC
    Cancer Res; 2009 Dec; 69(23):8886-93. PubMed ID: 19903840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coexpression analysis of CD133 and CD44 identifies proneural and mesenchymal subtypes of glioblastoma multiforme.
    Brown DV; Daniel PM; D'Abaco GM; Gogos A; Ng W; Morokoff AP; Mantamadiotis T
    Oncotarget; 2015 Mar; 6(8):6267-80. PubMed ID: 25749043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles.
    Beier D; Hau P; Proescholdt M; Lohmeier A; Wischhusen J; Oefner PJ; Aigner L; Brawanski A; Bogdahn U; Beier CP
    Cancer Res; 2007 May; 67(9):4010-5. PubMed ID: 17483311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HLA-E contributes to an immune-inhibitory phenotype of glioblastoma stem-like cells.
    Wolpert F; Roth P; Lamszus K; Tabatabai G; Weller M; Eisele G
    J Neuroimmunol; 2012 Sep; 250(1-2):27-34. PubMed ID: 22688424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy targeting glioma stem cells--insights and perspectives.
    Li Z; Lee JW; Mukherjee D; Ji J; Jeswani SP; Black KL; Yu JS
    Expert Opin Biol Ther; 2012 Feb; 12(2):165-78. PubMed ID: 22200324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of glioma stem cell marker CD133 and O6-methylguanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomas.
    He J; Shan Z; Li L; Liu F; Liu Z; Song M; Zhu H
    Oncol Rep; 2011 Nov; 26(5):1305-13. PubMed ID: 21769436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type 1 collagen as a potential niche component for CD133-positive glioblastoma cells.
    Motegi H; Kamoshima Y; Terasaka S; Kobayashi H; Houkin K
    Neuropathology; 2014 Aug; 34(4):378-85. PubMed ID: 24673436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ultrastructural difference between CD133-positive U251 glioma stem cells and normal U251 glioma cells.
    Yang B; Wang Y; Yang C; Ouyang W; Zhou F; Zhou Y; Xie C
    Ultrastruct Pathol; 2012 Dec; 36(6):404-8. PubMed ID: 23216238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "Neural Killer" Cells: Autologous Cytotoxic Neural Stem Cells for Fighting Glioma.
    Mutukula N; Elkabetz Y
    Cell Stem Cell; 2017 Apr; 20(4):426-428. PubMed ID: 28388425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The presence of stem cell marker-expressing cells is not prognostically significant in glioblastomas.
    Kim KJ; Lee KH; Kim HS; Moon KS; Jung TY; Jung S; Lee MC
    Neuropathology; 2011 Oct; 31(5):494-502. PubMed ID: 21269333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glioma cell populations grouped by different cell type markers drive brain tumor growth.
    Prestegarden L; Svendsen A; Wang J; Sleire L; Skaftnesmo KO; Bjerkvig R; Yan T; Askland L; Persson A; Sakariassen PØ; Enger PØ
    Cancer Res; 2010 Jun; 70(11):4274-9. PubMed ID: 20460538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of cancer stem cell markers CD133 and CD44 in locoregional recurrence of rectal cancer.
    Nagata T; Sakakura C; Komiyama S; Miyashita A; Nishio M; Murayama Y; Komatsu S; Shiozaki A; Kuriu Y; Ikoma H; Nakanishi M; Ichikawa D; Fujiwara H; Okamoto K; Ochiai T; Kokuba Y; Sonoyama T; Otsuji E
    Anticancer Res; 2011 Feb; 31(2):495-500. PubMed ID: 21378329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.